Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03613220
Title CompLEEment-1 Canadian Correlative Sub-Study (LEEomic)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + Ribociclib

Age Groups: adult | child | senior
Covered Countries CAN


No variant requirements are available.